Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Vaccibody CEO Bonde: Make Undefeatable Diseases Defeatable

This article was originally published in Scrip

Executive Summary

Norway-based vaccine company, Vaccibody, has recently begun the first stage of clinical trials with its immunotherapy VB10.16 for patients with cervical intraepithelial neoplasia (CIN 2/3). Dr. Martin Bonde, a biotech veteran who sold EpiTherapeutics ApS to Gilead Sciences Inc. earlier this year for $65m, is now its CEO. He tells Scrip about his new challenge to use Vaccibody's unique technology to treat CIN and make undefeatable diseases defeatable.

Advertisement

Related Content

Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register